Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Development of a novel prostate apoptosis response-4 (Par-4) protein entity with an extended duration of action for therapeutic treatment of cancer.

Kim K, Araujo P, Hebbar N, Zhou Z, Zheng X, Zheng F, Rangnekar VM, Zhan CG.

Protein Eng Des Sel. 2019 Nov 11. pii: gzz034. doi: 10.1093/protein/gzz034. [Epub ahead of print]

PMID:
31711233
2.

Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.

Greene JT, Mani R, Ramaswamy R, Frissora F, Yano M, Zapolnik K, Harrington B, Wasmuth R, Tran M, Mo X, McKenna M, Rangnekar VM, Byrd JC, Bondada S, Muthusamy N.

Blood Adv. 2019 Apr 23;3(8):1255-1266. doi: 10.1182/bloodadvances.2018025973.

3.

Neoadjuvant administration of hydroxychloroquine in a phase 1 clinical trial induced plasma Par-4 levels and apoptosis in diverse tumors.

Wang P, Burikhanov R, Jayswal R, Weiss HL, Arnold SM, Villano JL, Rangnekar VM.

Genes Cancer. 2018 May;9(5-6):190-197. doi: 10.18632/genesandcancer.181.

4.

GRP78 Is a Targetable Receptor on Cancer and Stromal Cells.

Araujo N, Hebbar N, Rangnekar VM.

EBioMedicine. 2018 Jul;33:2-3. doi: 10.1016/j.ebiom.2018.06.030. Epub 2018 Jul 8. No abstract available.

5.

Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.

Alhakeem SS, McKenna MK, Oben KZ, Noothi SK, Rivas JR, Hildebrandt GC, Fleischman RA, Rangnekar VM, Muthusamy N, Bondada S.

J Immunol. 2018 Jun 15;200(12):4180-4189. doi: 10.4049/jimmunol.1800241. Epub 2018 Apr 30.

6.

Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.

McKenna MK, Noothi SK, Alhakeem SS, Oben KZ, Greene JT, Mani R, Perry KL, Collard JP, Rivas JR, Hildebrandt GC, Fleischman RA, Durbin EB, Byrd JC, Wang C, Muthusamy N, Rangnekar VM, Bondada S.

Blood. 2018 Jun 28;131(26):2943-2954. doi: 10.1182/blood-2017-10-813931. Epub 2018 Apr 25.

7.

A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in Tumors.

Hebbar N, Burikhanov R, Shukla N, Qiu S, Zhao Y, Elenitoba-Johnson KSJ, Rangnekar VM.

Cancer Res. 2017 Aug 1;77(15):4039-4050. doi: 10.1158/0008-5472.CAN-16-1970. Epub 2017 Jun 16.

8.

Radiation Induced Apoptosis of Murine Bone Marrow Cells Is Independent of Early Growth Response 1 (EGR1).

Oben KZ, Gachuki BW, Alhakeem SS, McKenna MK, Liang Y, St Clair DK, Rangnekar VM, Bondada S.

PLoS One. 2017 Jan 12;12(1):e0169767. doi: 10.1371/journal.pone.0169767. eCollection 2017.

9.

Chloroquine-Inducible Par-4 Secretion Is Essential for Tumor Cell Apoptosis and Inhibition of Metastasis.

Burikhanov R, Hebbar N, Noothi SK, Shukla N, Sledziona J, Araujo N, Kudrimoti M, Wang QJ, Watt DS, Welch DR, Maranchie J, Harada A, Rangnekar VM.

Cell Rep. 2017 Jan 10;18(2):508-519. doi: 10.1016/j.celrep.2016.12.051.

10.

Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.

Singh AK, Chauhan SS, Singh SK, Verma VV, Singh A, Arya RK, Maheshwari S, Akhtar MS, Sarkar J, Rangnekar VM, Chauhan PMS, Datta D.

Carcinogenesis. 2016 Nov 1;37(11):1027-1040. doi: 10.1093/carcin/bgw088.

11.

Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.

Sviripa VM, Burikhanov R, Obiero JM, Yuan Y, Nickell JR, Dwoskin LP, Zhan CG, Liu C, Tsodikov OV, Rangnekar VM, Watt DS.

Org Biomol Chem. 2016 Jan 7;14(1):74-84. doi: 10.1039/c5ob01980j.

12.

Plant-derived SAC domain of PAR-4 (Prostate Apoptosis Response 4) exhibits growth inhibitory effects in prostate cancer cells.

Sarkar S, Jain S, Rai V, Sahoo DK, Raha S, Suklabaidya S, Senapati S, Rangnekar VM, Maiti IB, Dey N.

Front Plant Sci. 2015 Oct 7;6:822. doi: 10.3389/fpls.2015.00822. eCollection 2015.

13.

Development of 6H-Chromeno[3,4-c]pyrido[3',2':4,5]thieno[2,3-e]pyridazin-6-ones as Par-4 Secretagogues.

Frasinyuk MS, Bondarenko SP, Sviripa VM, Burikhanov R, Rangnekar VM, Liu C, Watt DS.

Tetrahedron Lett. 2015 Jun 3;56(23):3382-3384.

14.

Anti-cancer activity of withaferin A in B-cell lymphoma.

McKenna MK, Gachuki BW, Alhakeem SS, Oben KN, Rangnekar VM, Gupta RC, Bondada S.

Cancer Biol Ther. 2015;16(7):1088-98. doi: 10.1080/15384047.2015.1046651.

15.

Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis.

Burikhanov R, Sviripa VM, Hebbar N, Zhang W, Layton WJ, Hamza A, Zhan CG, Watt DS, Liu C, Rangnekar VM.

Nat Chem Biol. 2014 Nov;10(11):924-926. doi: 10.1038/nchembio.1631. Epub 2014 Sep 14.

16.

The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.

Liu Y, Gilbert MR, Kyprianou N, Rangnekar VM, Horbinski C.

Acta Neuropathol. 2014 Nov;128(5):723-32. doi: 10.1007/s00401-014-1334-7. Epub 2014 Aug 19.

17.

Cancer-selective apoptosis by tumor suppressor par-4.

Hebbar N, Shrestha-Bhattarai T, Rangnekar VM.

Adv Exp Med Biol. 2014;818:155-66. doi: 10.1007/978-1-4471-6458-6_7. Review.

PMID:
25001535
18.

Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival.

Chen X, Sahasrabuddhe AA, Szankasi P, Chung F, Basrur V, Rangnekar VM, Pagano M, Lim MS, Elenitoba-Johnson KS.

Cell Death Differ. 2014 Oct;21(10):1535-45. doi: 10.1038/cdd.2014.92. Epub 2014 Jul 4.

19.

Regulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cells.

de Thonel A, Hazoumé A, Kochin V, Isoniemi K, Jego G, Fourmaux E, Hammann A, Mjahed H, Filhol O, Micheau O, Rocchi P, Mezger V, Eriksson JE, Rangnekar VM, Garrido C.

Cell Death Dis. 2014 Jan 23;5:e1016. doi: 10.1038/cddis.2013.532.

20.

Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4.

Burikhanov R, Shrestha-Bhattarai T, Hebbar N, Qiu S, Zhao Y, Zambetti GP, Rangnekar VM.

Cell Rep. 2014 Jan 30;6(2):271-7. doi: 10.1016/j.celrep.2013.12.020. Epub 2014 Jan 9.

21.

Par-4 prevents breast cancer recurrence.

Hebbar N, Shrestha-Bhattarai T, Rangnekar VM.

Breast Cancer Res. 2013;15(5):314.

22.

Par(-4)oxysm in breast cancer.

Shrestha-Bhattarai T, Hebbar N, Rangnekar VM.

Cancer Cell. 2013 Jul 8;24(1):3-5. doi: 10.1016/j.ccr.2013.06.010.

23.

Prostate apoptosis response-4 is involved in the apoptosis response to docetaxel in MCF-7 breast cancer cells.

Pereira MC, de Bessa-Garcia SA, Burikhanov R, Pavanelli AC, Antunes L, Rangnekar VM, Nagai MA.

Int J Oncol. 2013 Aug;43(2):531-8. doi: 10.3892/ijo.2013.1983. Epub 2013 Jun 12.

24.

Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4.

Burikhanov R, Shrestha-Bhattarai T, Qiu S, Shukla N, Hebbar N, Lele SM, Horbinski C, Rangnekar VM.

Cancer Res. 2013 Jan 15;73(2):1011-9. doi: 10.1158/0008-5472.CAN-12-3212. Epub 2012 Nov 30.

25.

Mechanisms of apoptosis by the tumor suppressor Par-4.

Hebbar N, Wang C, Rangnekar VM.

J Cell Physiol. 2012 Dec;227(12):3715-21. doi: 10.1002/jcp.24098. Review.

26.

Nicotinic modulation of therapeutic response in vitro and in vivo.

Warren GW, Romano MA, Kudrimoti MR, Randall ME, McGarry RC, Singh AK, Rangnekar VM.

Int J Cancer. 2012 Dec 1;131(11):2519-27. doi: 10.1002/ijc.27556. Epub 2012 Apr 16.

27.

Accuracy of self-reported tobacco assessments in a head and neck cancer treatment population.

Warren GW, Arnold SM, Valentino JP, Gal TJ, Hyland AJ, Singh AK, Rangnekar VM, Cummings KM, Marshall JR, Kudrimoti MR.

Radiother Oncol. 2012 Apr;103(1):45-8. doi: 10.1016/j.radonc.2011.11.003. Epub 2011 Nov 25.

28.

Systemic Par-4 inhibits non-autochthonous tumor growth.

Zhao Y, Burikhanov R, Brandon J, Qiu S, Shelton BJ, Spear B, Bondada S, Bryson S, Rangnekar VM.

Cancer Biol Ther. 2011 Jul 15;12(2):152-7. Epub 2011 Jul 15.

29.

Cancer-selective apoptotic effects of extracellular and intracellular Par-4.

Shrestha-Bhattarai T, Rangnekar VM.

Oncogene. 2010 Jul 8;29(27):3873-80. doi: 10.1038/onc.2010.141. Epub 2010 May 3. Review.

30.

Targeting plasma membrane GRP78 for cancer growth inhibition.

Schwarze S, Rangnekar VM.

Cancer Biol Ther. 2010 Jan;9(2):153-5. Epub 2010 Jan 26. No abstract available.

PMID:
20026905
31.

The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis.

Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM.

Cell. 2009 Jul 23;138(2):377-88. doi: 10.1016/j.cell.2009.05.022. Erratum in: Cell. 2009 Sep 4;138(5):1032.

32.

RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN.

Park S, Zhao D, Hatanpaa KJ, Mickey BE, Saha D, Boothman DA, Story MD, Wong ET, Burma S, Georgescu MM, Rangnekar VM, Chauncey SS, Habib AA.

Cancer Res. 2009 May 15;69(10):4107-11. doi: 10.1158/0008-5472.CAN-09-0474. Epub 2009 May 12.

33.

Apoptosis and tumor resistance conferred by Par-4.

Zhao Y, Rangnekar VM.

Cancer Biol Ther. 2008 Dec;7(12):1867-74. Epub 2008 Dec 8. Review.

34.

Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis.

Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J, Wang S, Sarkar FH, Mohammad RM.

Mol Cancer Ther. 2008 Sep;7(9):2884-93. doi: 10.1158/1535-7163.MCT-08-0438.

35.

ErbB4 targeting approaches for prostate cancer treatment.

Wheeler DL, Rangnekar VM, Schwarze SR.

Cancer Biol Ther. 2008 Jul;7(7):1095-7. Epub 2008 Jun 30. No abstract available.

PMID:
18698169
36.

Par-4 binds to topoisomerase 1 and attenuates its DNA relaxation activity.

Goswami A, Qiu S, Dexheimer TS, Ranganathan P, Burikhanov R, Pommier Y, Rangnekar VM.

Cancer Res. 2008 Aug 1;68(15):6190-8. doi: 10.1158/0008-5472.CAN-08-0831.

37.

Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM).

Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH.

Pharm Res. 2008 Sep;25(9):2117-24. doi: 10.1007/s11095-008-9581-8. Epub 2008 Apr 22.

38.

Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma.

Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, Shajahan S, Mohiuddin M, Rangnekar VM, Ahmed MM.

Cancer Res. 2007 Dec 15;67(24):11811-20.

39.

Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras.

Vasudevan KM, Burikhanov R, Goswami A, Rangnekar VM.

Cancer Res. 2007 Nov 1;67(21):10343-50.

40.

Cancer resistance in transgenic mice expressing the SAC module of Par-4.

Zhao Y, Burikhanov R, Qiu S, Lele SM, Jennings CD, Bondada S, Spear B, Rangnekar VM.

Cancer Res. 2007 Oct 1;67(19):9276-85.

41.

The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.

Sun Y, St Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA, St Clair WH.

Mol Cancer Ther. 2007 Sep;6(9):2477-86.

42.

"D" approach to prevent metastasis.

Languino LR, Rangnekar VM.

Cancer Biol Ther. 2007 Jan;6(1):110-1. No abstract available.

PMID:
17264669
43.

Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.

Gururajan M, Dasu T, Shahidain S, Jennings CD, Robertson DA, Rangnekar VM, Bondada S.

J Immunol. 2007 Jan 1;178(1):111-21.

44.

Regulation of Par-4 by oncogenic Ras.

Vasudevan KM, Ranganathan P, Rangnekar VM.

Methods Enzymol. 2006;407:422-42.

PMID:
16757343
45.

The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target.

Goswami A, Ranganathan P, Rangnekar VM.

Cancer Res. 2006 Mar 15;66(6):2889-92. Review.

46.

Regulation of cancer cell survival by Par-4.

Ranganathan P, Rangnekar VM.

Ann N Y Acad Sci. 2005 Nov;1059:76-85. Review.

PMID:
16382046
47.

Binding and phosphorylation of par-4 by akt is essential for cancer cell survival.

Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y, Eriksson JE, Tsuruo T, Rangnekar VM.

Mol Cell. 2005 Oct 7;20(1):33-44.

48.

Exploiting the TSA connections to overcome apoptosis-resistance.

Ranganathan P, Rangnekar VM.

Cancer Biol Ther. 2005 Apr;4(4):391-2. Epub 2005 Apr 29. No abstract available.

PMID:
15908800
49.

Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells.

Pruitt K, Ulkü AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, Der CJ, Shields JM.

J Biol Chem. 2005 Jun 17;280(24):23363-70. Epub 2005 Apr 14.

50.

Phosphorylation of Par-4 by protein kinase A is critical for apoptosis.

Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM.

Mol Cell Biol. 2005 Feb;25(3):1146-61.

Supplemental Content

Loading ...
Support Center